IBRX Stock Declines Pre-Market - Immunitybio Resubmits Anktiva Application To FDA With Additional Data

RunWithRugs · 2026-03-09T17:25:27+00:00

ImmunityBio has resubmitted its supplemental BLA for Anktiva to the FDA, including additional requested information for papillary disease. The company's shares fell over 5%, with bearish sentiment noted on Stocktwits.

RunWithRugs

2026-03-09 17:25:27

Abstract generation in progress

(MENAFN- AsiaNet News)

ImmunityBio Inc. (IBRX) on Monday announced that it has resubmitted the supplemental biologics license application (BLA) to the U.S. Food and Drug Administration for Anktiva.

ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.

ImmunityBio shares were down more than 5% in Monday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.

Get updates to this developing story directly on Stocktwits.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

MENAFN09032026000070015968ID1110836477

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes